KRAS and adenocarcinoma: To date, two-thirds of Japanese adenocarcinomas and a little more than half of Caucasian adenocarcinomas have mutually exclusive oncogenic mutations or other genetic alterations including EGFR, KRAS, MET, ALK and HER2 (27).